专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US08137932B2 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment 有权
标题翻译：用于稳定嵌合免疫球蛋白或免疫球蛋白片段的方法和稳定的抗EGP-2 scFv片段
公开(公告)号：US08137932B2
公开(公告)日：2012-03-20
申请号：US12961751
申请日：2010-12-07
申请人： Andreas Plückthun , Annemarie Honegger , Jörg Willuda
发明人： Andreas Plückthun , Annemarie Honegger , Jörg Willuda
IPC分类号： C07H21/00 , C12P21/02
CPC分类号： C07K16/00 , A61K47/6813 , A61K47/6819 , A61K47/6821 , A61K47/6823 , A61K47/6825 , A61K47/6829 , A61K47/6851 , A61K47/6877 , A61K51/1045 , A61K51/1087 , A61K2039/505 , C07K16/06 , C07K16/28 , C07K16/30 , C07K16/465 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/92
摘要： The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
摘要翻译：本发明涉及稳定嵌合免疫球蛋白或免疫球蛋白片段的方法。此外，本发明还提供了稳定的抗EGP-2 scFv片段。

72. 发明申请

US20110250168A1 Sialoadhesin-related compositions and methods 审中-公开
标题翻译：唾液酸相关组合物和方法
公开(公告)号：US20110250168A1
公开(公告)日：2011-10-13
申请号：US13066341
申请日：2011-04-11
申请人： Hans Nauwynck , Peter Delputte
发明人： Hans Nauwynck , Peter Delputte
IPC分类号： A61K39/395 , A61K39/385 , A61K48/00 , A61P35/00 , C12N15/85 , A61K38/20 , A61P31/12 , A61P37/02 , C12N5/00 , A61K38/21
CPC分类号： A61K47/6849 , A61K47/646 , A61K47/6811 , A61K47/6813 , A61K47/6825
摘要： Methods of delivering a cargo moiety to a cell is provided according to embodiments of the invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods provided by the invention include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided by the invention.
摘要翻译：根据本发明的实施方案提供将货物部分递送到细胞的方法，其包括使表达唾液酸粘附素的细胞与包含唾液酸粘附素结合部分和货物部分的缀合物接触。唾液酸粘附素结合部分结合由细胞表达的唾液酸粘附素，并与货物一起内化，将货物部分输送至细胞。本发明提供的具体方法包括在天然产生很少或不含唾液酸粘蛋白的细胞中诱导或增强唾液酸粘附素表达。唾液酸粘附素表达的诱导或增强包括转染唾液酸粘附素表达构建体和/或施用有效诱导或增强唾液酸粘附素表达的试剂。详细说明刺激受试者免疫应答的方法和组合物。用于刺激对病毒的免疫应答的特定方法和组合物由本发明提供。

73. 发明授权

US08034352B2 Tetrameric cytokines with improved biological activity 有权
标题翻译：具有改善的生物活性的四聚体细胞因子
公开(公告)号：US08034352B2
公开(公告)日：2011-10-11
申请号：US12752649
申请日：2010-04-01
申请人： Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
发明人： Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
IPC分类号： A61K39/00 , A61K38/21 , A61K38/18 , A61K39/385 , C07K16/28 , C07K16/30 , C07K14/505 , C07K14/535 , C07K14/56
CPC分类号： A61K47/48423 , A61K39/395 , A61K47/65 , A61K47/6813 , A61K47/6853 , A61K51/1048 , A61K2039/505 , B82Y5/00 , B82Y10/00 , B82Y30/00 , C07K16/2803 , C07K16/283 , C07K16/2833 , C07K16/2863 , C07K16/2887 , C07K16/3007 , C07K16/44 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C07K2319/70
摘要： The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.
摘要翻译：本发明涉及使用基座和锁定技术形成细胞因子 - 抗体复合物的方法和组合物。在优选的实施方案中，细胞因子-MAb DNL复合物包含连接到两个AD（锚结构域）部分的IgG抗体和四个细胞因子，每个连接到DDD（对接和二聚化结构域）部分。 DDD部分形成与AD部分结合的二聚体，导致DDD与AD的比例为2:1。细胞因子-MAb复合物表现出改善的药代动力学，其具有比裸细胞因子或聚乙二醇化细胞因子显着更长的血清半衰期。细胞因子-MAb复合物与单独的细胞因子，单独的抗体，未缀合的细胞因子+抗体或掺入无关抗体的细胞因子-MAb DNL复合物相比，还显示出显着改善的体外和体内功效。在更优选的实施方案中，细胞因子是G-CSF，红细胞生成素或INF-α2b。

74. 发明申请

US20110159540A1 Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins 审中-公开
标题翻译：化学合成免疫球蛋白嵌合蛋白的方法
公开(公告)号：US20110159540A1
公开(公告)日：2011-06-30
申请号：US12910265
申请日：2010-10-22
申请人： Adam R. MEZO , Robert T. Peters
发明人： Adam R. MEZO , Robert T. Peters
IPC分类号： C12P21/00 , C07K19/00 , C07K16/00
CPC分类号： C07K14/755 , A61K38/00 , A61K47/60 , A61K47/642 , A61K47/68 , A61K47/6803 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/475 , C07K14/505 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/59 , C07K14/61 , C07K14/70503 , C07K14/745 , C07K16/00 , C07K2317/52 , C07K2319/00 , C07K2319/30 , C12N9/6437 , C12N9/644 , C12N9/647 , C12N9/96 , C12Y304/21021 , C12Y304/21022
摘要： The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.
摘要翻译：本发明提供了化学合成包含免疫球蛋白恒定区和生物活性分子的至少一部分的嵌合蛋白的方法。

75. 发明授权

US07951356B1 Tissue factor compositions and kits for coagulation and tumor treatment 失效
标题翻译：用于凝血和肿瘤治疗的组织因子组合物和试剂盒
公开(公告)号：US07951356B1
公开(公告)日：2011-05-31
申请号：US09573835
申请日：2000-05-18
申请人： Philip E. Thorpe , Steven W. King , Boning Gao
发明人： Philip E. Thorpe , Steven W. King , Boning Gao
IPC分类号： A61K38/16 , A61K38/36 , A61K38/37 , A61K47/30 , A61K47/48
CPC分类号： A61K47/6813 , A61K47/6435 , Y10S514/834 , Y10S530/827 , Y10S530/829
摘要： The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
摘要翻译：本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的用于组合凝血剂的组织因子的方法和组合物。本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVIIa激活剂。

76. 发明申请

US20110064751A1 TARGETED IMMUNOCONJUGATES 有权
标题翻译：有针对性的免疫球蛋白
公开(公告)号：US20110064751A1
公开(公告)日：2011-03-17
申请号：US12857882
申请日：2010-08-17
申请人： Ekkehard Mössner , Ralf Jörg Hosse , Pablo Umaña , Michela Silacci-Melkko
发明人： Ekkehard Mössner , Ralf Jörg Hosse , Pablo Umaña , Michela Silacci-Melkko
IPC分类号： A61K39/395 , C07K16/00 , C07K16/40 , C07K16/30 , C07K16/18 , C07K14/52 , C07K14/535 , C07K14/55 , C07K14/54 , C07K14/56 , C07H21/00 , C12N15/63 , C12N5/10 , C12P21/02 , A61P35/00
CPC分类号： C07K16/00 , A61K47/48423 , A61K47/48538 , A61K47/48646 , A61K47/6813 , A61K47/6843 , A61K47/6871 , A61K2039/505 , C07K16/18 , C07K16/40 , C07K16/468 , C07K2317/73 , C07K2317/74 , C07K2317/92
摘要： The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
摘要翻译：本发明涉及免疫缀合物。在具体实施方案中，本发明涉及包含至少一个单链效应子部分和两个或更多个抗原结合部分的免疫缀合物。此外，本发明涉及编码这种免疫缀合物的核酸分子，载体和包含该核酸分子的宿主细胞。本发明还涉及本发明的免疫缀合物的制备方法，以及使用这些免疫缀合物治疗疾病的方法。

77. 发明授权

US07906118B2 Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology 有权
标题翻译：通过对接和锁定（DNL）技术制备具有改善的药代动力学的四聚体细胞因子的模块化方法
公开(公告)号：US07906118B2
公开(公告)日：2011-03-15
申请号：US12418877
申请日：2009-04-06
申请人： Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
发明人： Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
IPC分类号： A61K39/395 , A61K39/44 , A61K38/19 , A61K38/21 , A61K38/20 , C07K14/00 , C07K14/52 , C07K16/46 , C12P21/08
CPC分类号： C12N9/96 , A61K39/395 , A61K47/65 , A61K47/6813 , A61K47/6853 , A61K51/1048 , B82Y5/00 , B82Y10/00 , B82Y30/00 , C07K16/283 , C07K16/3007 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C07K2319/70
摘要： The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes.
摘要翻译：本发明涉及使用基座和锁定技术形成细胞因子 - 抗体复合物的方法和组合物。在优选的实施方案中，细胞因子-MAb DNL复合物包含连接到两个AD（锚结构域）部分的IgG抗体和四个细胞因子，每个连接到DDD（对接和二聚化结构域）部分。 DDD部分形成与AD部分结合的二聚体，导致DDD与AD的比例为2:1。细胞因子-MAb复合物表现出改善的药代动力学，其具有比裸细胞因子或聚乙二醇化细胞因子显着更长的血清半衰期。细胞因子-MAb复合物与单独的细胞因子，单独的抗体，未缀合的细胞因子+抗体或掺入无关抗体的细胞因子-MAb DNL复合物相比，还显示出显着改善的体外和体内功效。在最优选的实施方案中，复合物包含与四个IFN-α2b部分缀合的抗CD20IgG抗体，尽管已经使用其他抗体和细胞因子来形成效应DNL复合物。

78. 发明授权

US07862820B2 Immunoglobulin chimeric monomer-dimer hybrids 有权
标题翻译：免疫球蛋白嵌合单体 - 二聚体杂交体
公开(公告)号：US07862820B2
公开(公告)日：2011-01-04
申请号：US11588431
申请日：2006-10-27
申请人： Robert T. Peters , Adam R. Mezo , Daniel S. Rivera , Alan J. Bitonti , Susan C. Low
发明人： Robert T. Peters , Adam R. Mezo , Daniel S. Rivera , Alan J. Bitonti , Susan C. Low
IPC分类号： A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K14/755 , A61K38/00 , A61K47/60 , A61K47/642 , A61K47/68 , A61K47/6803 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/475 , C07K14/505 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/59 , C07K14/61 , C07K14/70503 , C07K14/745 , C07K16/00 , C07K2317/52 , C07K2319/00 , C07K2319/30 , C12N9/6437 , C12N9/644 , C12N9/647 , C12N9/96 , C12Y304/21021 , C12Y304/21022
摘要： The invention relates to a chimeric monomer-dimer hybrid protein that comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first polypeptide chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
摘要翻译：本发明涉及包含第一和第二多肽链的嵌合单体 - 二聚体杂合蛋白，所述第一多肽链包含至少一部分免疫球蛋白恒定区和生物活性分子，第二多肽链包含至少一个部分免疫球蛋白恒定区，而没有第一多肽链的生物活性分子。本发明还涉及制备本发明的嵌合单体 - 二聚体杂交蛋白质的方法和方法。

79. 发明申请

US20100330108A1 PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE 有权
标题翻译：用于治疗包含胰岛素相关疾病的相关疾病的药物组合物
公开(公告)号：US20100330108A1
公开(公告)日：2010-12-30
申请号：US12744660
申请日：2008-11-28
申请人： Dae Hae Song , Min Young Kim , Young Jin Park , Eun Hee Kang , Sung Youb Jung , Se Chang Kwon , Gwan Sun Lee
发明人： Dae Hae Song , Min Young Kim , Young Jin Park , Eun Hee Kang , Sung Youb Jung , Se Chang Kwon , Gwan Sun Lee
IPC分类号： A61K39/00 , A61P3/06 , A61P3/10 , A61P9/00 , C07K16/00
CPC分类号： C07K19/00 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K2319/30
摘要： The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.
摘要翻译：本发明涉及一种用于治疗肥胖相关疾病的组合物，其包括促胰岛素肽缀合物，更具体地，涉及用于治疗肥胖相关疾病的组合物，其包含通过非肽基共价连接促胰岛素肽与载体物质而制备的缀合物接头，以及通过使用它们来治疗肥胖相关疾病的方法。特别地，本发明的治疗肥胖相关疾病的组合物显着地提高了抑制食物摄取的效果及其减轻体重和体脂的持续时间，从而可用于治疗肥胖相关疾病。

80. 发明申请

US20100260707A1 ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS 有权
标题翻译：抗生素与抗炎药相关
公开(公告)号：US20100260707A1
公开(公告)日：2010-10-14
申请号：US12740641
申请日：2008-10-27
申请人： Manuela Kaspar , Kathrin Schwager , Eveline Trachsel
发明人： Manuela Kaspar , Kathrin Schwager , Eveline Trachsel
IPC分类号： A61K38/20 , G01N33/53 , A61P29/00
CPC分类号： C07K16/18 , A61K47/48423 , A61K47/48538 , A61K47/6813 , A61K47/6843 , A61K51/1018 , A61K2039/505 , C07K2317/21 , C07K2317/622 , C07K2317/92 , C07K2319/00
摘要： The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
摘要翻译：本发明涉及结合纤维连接蛋白的Extra-A（ED-A）同种型用于检测和治疗类风湿性关节炎的结合成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式